Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Shepherd

Showing results (961-970 of 1,281) with videos related to

Pageof 129
Sort By:
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Current Developments in Nutrition|May 7, 2021
Diet Quality and Visceral Adiposity among a Multiethnic Population of Young, Middle, and Older Aged AdultsChloe E Panizza, Michael C Wong, Nisa Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancerMing-Sound Tsao, Sarit Aviel-Ronen, Keyue Ding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24R Goodwin, K Ding, L Seymour, et al.
Clinical Lung Cancer|October 31, 2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortiumScott A Laurie, Glenwood D Goss, Frances A Shepherd, et al.
Clinical Lung Cancer|February 25, 2019
Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care SystemDoreen A Ezeife, Brandon Josh Morganstein, Sally Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.
Clinical Lung Cancer|November 5, 2003
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancerNatasha B Leighl, Ronald L Burkes, Janet E Dancey, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
Aerospace Medicine and Human Performance|December 18, 2020
A Novel Method to Measure Transient Impairments in Cognitive Function During Acute Bouts of HypoxiaKoji Uchida, Sarah E Baker, Chad C Wiggins, et al.
Pageof 129

Showing results (961-970 of 1,281) with videos related to

Sort By:
Pageof 129
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line settingMartin Reck, Marina Chiara Garassino, Martina Imbimbo, et al.
Current Developments in Nutrition|May 7, 2021
Diet Quality and Visceral Adiposity among a Multiethnic Population of Young, Middle, and Older Aged AdultsChloe E Panizza, Michael C Wong, Nisa Kelly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 21, 2007
Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancerMing-Sound Tsao, Sarit Aviel-Ronen, Keyue Ding, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 30, 2010
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24R Goodwin, K Ding, L Seymour, et al.
Clinical Lung Cancer|October 31, 2013
A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortiumScott A Laurie, Glenwood D Goss, Frances A Shepherd, et al.
Clinical Lung Cancer|February 25, 2019
Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care SystemDoreen A Ezeife, Brandon Josh Morganstein, Sally Lau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 25, 2009
Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitorsJ-C Soria, F A Shepherd, J-Y Douillard, et al.
Clinical Lung Cancer|November 5, 2003
A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancerNatasha B Leighl, Ronald L Burkes, Janet E Dancey, et al.
Lung Cancer (Amsterdam, Netherlands)|November 21, 2012
Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancerKatsuyuki Hotta, Etsuji Suzuki, Massimo Di Maio, et al.
Aerospace Medicine and Human Performance|December 18, 2020
A Novel Method to Measure Transient Impairments in Cognitive Function During Acute Bouts of HypoxiaKoji Uchida, Sarah E Baker, Chad C Wiggins, et al.
Pageof 129